Assetmark Inc. Acquires 14,595 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Assetmark Inc. grew its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 21.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 81,554 shares of the medical equipment provider’s stock after purchasing an additional 14,595 shares during the quarter. Assetmark Inc.’s holdings in Intuitive Surgical were worth $40,065,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Creekmur Asset Management LLC grew its stake in Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 42 shares in the last quarter. Ridgewood Investments LLC bought a new position in Intuitive Surgical in the second quarter worth approximately $26,000. Delos Wealth Advisors LLC grew its stake in Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 57 shares in the last quarter. Godsey & Gibb Inc. increased its holdings in Intuitive Surgical by 140.0% during the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 35 shares during the period. Finally, LRI Investments LLC bought a new stake in Intuitive Surgical during the 1st quarter valued at $30,000. 83.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Evercore ISI reissued a “cautious” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. Wells Fargo & Company increased their target price on shares of Intuitive Surgical from $466.00 to $549.00 and gave the stock an “overweight” rating in a report on Friday, October 18th. Mizuho boosted their price target on shares of Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price objective for the company from $380.00 to $510.00 in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Intuitive Surgical from $495.00 to $575.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $513.74.

Insider Buying and Selling

In other Intuitive Surgical news, EVP Robert Desantis sold 240 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $464.76, for a total transaction of $111,542.40. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at approximately $2,558,968.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Intuitive Surgical news, CEO Gary S. Guthart sold 18,151 shares of Intuitive Surgical stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $511.63, for a total transaction of $9,286,596.13. Following the completion of the sale, the chief executive officer now directly owns 24,219 shares in the company, valued at approximately $12,391,166.97. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Robert Desantis sold 240 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $464.76, for a total transaction of $111,542.40. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at $2,558,968.56. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 68,246 shares of company stock worth $33,839,308 in the last 90 days. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $536.45 on Friday. The firm has a market capitalization of $191.07 billion, a price-to-earnings ratio of 86.25, a PEG ratio of 5.07 and a beta of 1.39. The stock’s 50-day simple moving average is $493.92 and its 200-day simple moving average is $451.73. Intuitive Surgical, Inc. has a fifty-two week low of $269.49 and a fifty-two week high of $538.49.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. The business had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. As a group, equities analysts forecast that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.